1. Home
  2. CBAT vs SPRO Comparison

CBAT vs SPRO Comparison

Compare CBAT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBAT
  • SPRO
  • Stock Information
  • Founded
  • CBAT 1999
  • SPRO 2013
  • Country
  • CBAT China
  • SPRO United States
  • Employees
  • CBAT N/A
  • SPRO N/A
  • Industry
  • CBAT Industrial Machinery/Components
  • SPRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CBAT Miscellaneous
  • SPRO Health Care
  • Exchange
  • CBAT Nasdaq
  • SPRO Nasdaq
  • Market Cap
  • CBAT 75.2M
  • SPRO 63.0M
  • IPO Year
  • CBAT N/A
  • SPRO 2017
  • Fundamental
  • Price
  • CBAT $0.86
  • SPRO $1.05
  • Analyst Decision
  • CBAT
  • SPRO Buy
  • Analyst Count
  • CBAT 0
  • SPRO 3
  • Target Price
  • CBAT N/A
  • SPRO $5.00
  • AVG Volume (30 Days)
  • CBAT 261.4K
  • SPRO 205.6K
  • Earning Date
  • CBAT 11-12-2024
  • SPRO 11-14-2024
  • Dividend Yield
  • CBAT N/A
  • SPRO N/A
  • EPS Growth
  • CBAT N/A
  • SPRO N/A
  • EPS
  • CBAT 0.12
  • SPRO 0.06
  • Revenue
  • CBAT $207,423,403.00
  • SPRO $106,455,000.00
  • Revenue This Year
  • CBAT $10.76
  • SPRO N/A
  • Revenue Next Year
  • CBAT $15.32
  • SPRO N/A
  • P/E Ratio
  • CBAT $6.95
  • SPRO $16.37
  • Revenue Growth
  • CBAT 2.32
  • SPRO 37.01
  • 52 Week Low
  • CBAT $0.82
  • SPRO $1.01
  • 52 Week High
  • CBAT $2.08
  • SPRO $1.89
  • Technical
  • Relative Strength Index (RSI)
  • CBAT 38.12
  • SPRO 31.12
  • Support Level
  • CBAT $0.82
  • SPRO $1.12
  • Resistance Level
  • CBAT $0.89
  • SPRO $1.20
  • Average True Range (ATR)
  • CBAT 0.05
  • SPRO 0.04
  • MACD
  • CBAT -0.00
  • SPRO -0.01
  • Stochastic Oscillator
  • CBAT 14.23
  • SPRO 13.67

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization and distribution of a variety of standard and customized lithium-ion high-power rechargeable batteries. The company operates in two operating segments: CBAK's segment mainly includes the manufacture, commercialization and distribution of a wide variety of standard and customized lithium ion rechargeable batteries for use in a wide array of applications. Hitrans' segment mainly includes the development and manufacturing of NCM precursor and cathode materials. Geographically, it generates a majority of its revenue from Mainland China and also has an operation in Europe, the United States, Korea, and Other Countries.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: